JP2022510964A5 - - Google Patents
Info
- Publication number
- JP2022510964A5 JP2022510964A5 JP2021531128A JP2021531128A JP2022510964A5 JP 2022510964 A5 JP2022510964 A5 JP 2022510964A5 JP 2021531128 A JP2021531128 A JP 2021531128A JP 2021531128 A JP2021531128 A JP 2021531128A JP 2022510964 A5 JP2022510964 A5 JP 2022510964A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- amino acid
- binding molecule
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024192042A JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781689P | 2018-12-19 | 2018-12-19 | |
| US62/781,689 | 2018-12-19 | ||
| PCT/US2019/067173 WO2020132066A1 (en) | 2018-12-19 | 2019-12-18 | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192042A Division JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510964A JP2022510964A (ja) | 2022-01-28 |
| JP2022510964A5 true JP2022510964A5 (https=) | 2022-12-26 |
| JP7637052B2 JP7637052B2 (ja) | 2025-02-27 |
Family
ID=69182681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531128A Active JP7637052B2 (ja) | 2018-12-19 | 2019-12-18 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
| JP2024192042A Pending JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192042A Pending JP2025013425A (ja) | 2018-12-19 | 2024-10-31 | 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11396544B2 (https=) |
| EP (1) | EP3897715A1 (https=) |
| JP (2) | JP7637052B2 (https=) |
| KR (1) | KR20210104836A (https=) |
| CN (1) | CN113164598B (https=) |
| AU (1) | AU2019405747A1 (https=) |
| BR (1) | BR112021010238A2 (https=) |
| CA (1) | CA3124168A1 (https=) |
| CL (1) | CL2021001630A1 (https=) |
| CO (1) | CO2021009004A2 (https=) |
| EA (1) | EA202191580A1 (https=) |
| IL (1) | IL283945A (https=) |
| MA (1) | MA54540A (https=) |
| MX (1) | MX2021007497A (https=) |
| MY (1) | MY206140A (https=) |
| PH (1) | PH12021551401A1 (https=) |
| WO (1) | WO2020132066A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279354B1 (en) * | 2018-06-21 | 2026-02-01 | Regeneron Pharma | Bispecific antibodies against psma and against cd28 and their uses |
| MA54540A (fr) | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
| CA3134335A1 (en) * | 2019-03-22 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| MX2023003214A (es) | 2020-09-18 | 2023-05-24 | Regeneron Pharma | Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas. |
| AU2021374803A1 (en) * | 2020-11-03 | 2023-06-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
| MX2023008081A (es) | 2021-01-11 | 2023-09-12 | Sana Biotechnology Inc | Uso de vectores virales dirigidos a cd8. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| IL314916A (en) | 2022-03-07 | 2024-10-01 | Novimmune Sa | Bispecific CD28 antibodies for targeted T cell activation |
| EP4493592A1 (en) | 2022-03-14 | 2025-01-22 | LamKap Bio gamma AG | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN119013295A (zh) * | 2022-04-11 | 2024-11-22 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和cd28的抗原结合分子及其医药用途 |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN117264065B (zh) * | 2022-06-15 | 2025-11-18 | 三优生物医药(上海)有限公司 | 一种her2抗原结合分子及其应用 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024077268A2 (en) * | 2022-10-07 | 2024-04-11 | Fred Hutchinson Cancer Center | Human metapneumovirus antibodies and uses thereof |
| US20240254234A1 (en) | 2022-10-21 | 2024-08-01 | Novimmune Sa | PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION |
| IL323074A (en) | 2023-03-13 | 2025-10-01 | Regeneron Pharma | Methods for treating cancer with anti-CD22 x anti-CD28 bispecific molecules |
| CN120904324A (zh) * | 2024-04-30 | 2025-11-07 | 惠和生物技术(上海)有限公司 | 抗cd28抗体及其用途 |
| WO2026078067A1 (en) | 2024-10-08 | 2026-04-16 | Novimmune Sa | Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US8496927B2 (en) | 2006-09-25 | 2013-07-30 | National University Corporation Nagoya University | CD20 negatively converted B-cell malignant lymphoma cell line and utilization thereof |
| US20130079353A1 (en) | 2009-12-22 | 2013-03-28 | Karsten Gülow | Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| WO2012171020A1 (en) * | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014044793A2 (en) | 2012-09-20 | 2014-03-27 | Max-Delbrück-Centrum für Molekulare Medizin | Cd22-binding peptides |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| CN113286811B (zh) * | 2018-07-30 | 2024-12-06 | 南加利福尼亚大学 | 改善过继性细胞疗法的效力和安全性 |
| CN109021114B (zh) * | 2018-08-08 | 2020-06-09 | 武汉波睿达生物科技有限公司 | 联合两种单链抗体的双特异性嵌合抗原受体及表达载体 |
| MA54540A (fr) * | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
-
2019
- 2019-12-18 MA MA054540A patent/MA54540A/fr unknown
- 2019-12-18 EP EP19839551.9A patent/EP3897715A1/en active Pending
- 2019-12-18 CA CA3124168A patent/CA3124168A1/en active Pending
- 2019-12-18 PH PH1/2021/551401A patent/PH12021551401A1/en unknown
- 2019-12-18 AU AU2019405747A patent/AU2019405747A1/en active Pending
- 2019-12-18 EA EA202191580A patent/EA202191580A1/ru unknown
- 2019-12-18 MX MX2021007497A patent/MX2021007497A/es unknown
- 2019-12-18 CN CN201980080109.1A patent/CN113164598B/zh active Active
- 2019-12-18 US US16/719,015 patent/US11396544B2/en active Active
- 2019-12-18 JP JP2021531128A patent/JP7637052B2/ja active Active
- 2019-12-18 BR BR112021010238-8A patent/BR112021010238A2/pt unknown
- 2019-12-18 KR KR1020217022524A patent/KR20210104836A/ko active Pending
- 2019-12-18 MY MYPI2021003083A patent/MY206140A/en unknown
- 2019-12-18 WO PCT/US2019/067173 patent/WO2020132066A1/en not_active Ceased
-
2021
- 2021-06-13 IL IL283945A patent/IL283945A/en unknown
- 2021-06-17 CL CL2021001630A patent/CL2021001630A1/es unknown
- 2021-07-08 CO CONC2021/0009004A patent/CO2021009004A2/es unknown
-
2022
- 2022-06-21 US US17/844,814 patent/US20230174652A1/en not_active Abandoned
-
2024
- 2024-10-31 JP JP2024192042A patent/JP2025013425A/ja active Pending
-
2025
- 2025-01-30 US US19/040,913 patent/US20250223360A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510964A5 (https=) | ||
| JP2022515611A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2021531005A5 (https=) | ||
| FI3823664T3 (fi) | Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä | |
| JP2020528768A5 (https=) | ||
| JP2017510559A5 (https=) | ||
| JP2021524249A5 (https=) | ||
| JP2023543152A5 (https=) | ||
| JP2019107018A5 (https=) | ||
| JP2021518103A5 (https=) | ||
| JP2021524244A5 (https=) | ||
| JP2014531201A5 (https=) | ||
| JP2018534933A5 (https=) | ||
| JP2013542194A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| JP2018519263A5 (https=) | ||
| JP2018500014A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2010513303A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| JP2023055904A5 (https=) | ||
| JP2024520666A5 (https=) |